Microencapsulation system for oral microbiome balance
A novel microencapsulated mouthwash designed to maintain oral microbiome balance by releasing active ingredients only in dysbiotic regions, sparing beneficial bacteria. It uses polyphenol-based actives to reduce biofilm and inflammation, ensuring targeted and sustainable oral health.
Overview
The microencapsulation system for oral microbiome balance is an innovative mouthwash solution designed to maintain the balance of the oral microbiome and prevent gingivitis-related dysbiosis. This mouthwash utilizes microencapsulated, stimuli-responsive capsules that release virulence inhibitors and low-dose reactive oxygen species specifically in pathogenic regions, preserving beneficial bacteria. The inclusion of prebiotic and postbiotic components further supports beneficial microbes and enhances pathogen suppression. Polyphenol-based actives within the formulation contribute to reduced biofilm formation and inflammation, providing a targeted and sustainable approach to oral health.
Technical specifications
- Stimuli-responsive microcapsules: Activate only under dysbiotic conditions, enabling targeted release of active ingredients.
- Polyphenol-based actives: Contribute to reduced biofilm formation and inflammation.
- Prebiotic and postbiotic components: Support the growth and recovery of beneficial bacteria, reinforcing microbiome balance.
- Localized and controlled release: Ensures targeted action without unnecessary intervention, promoting safe and effective oral health maintenance.
Technology readiness level
The technology is currently at TRL 2, with plans for validation phases that include microcapsule formulation optimization, pH-responsive release testing using in vitro biofilm models, and evaluations of stability, safety, and formulation compatibility to develop a prototype mouthwash.
About Monash University, Melbourne
Monash University is a comprehensive public research university and one of Australia’s largest, known for scale, interdisciplinarity, and an applied orientation. Its Melbourne-based technology precinct brings together university laboratories, pilot-scale and prototyping suites, and company R&D groups alongside government research organizations to enable co-development and rapid iteration. Integration with a major hospital network supports clinical trials and translation, while structured industry placements and doctoral partnerships create a robust talent pipeline for corporate R&D. Research is backed by competitive funding from the Australian Research Council, the National Health and Medical Research Council, and state and federal programs that incentivize industry collaboration. A dedicated technology transfer office manages IP, licensing, and startup formation, with pathways to incubation and investment within the precinct.
delivered to your inbox.